Grünenthal Press Releases 2013

Welcome to Grünenthal's Press Overview

19 Apr 2013

Grünenthal Highlights Significant R&D Advances in Pain, Inflammation as well as INTAC® Tamper-Resistant Technology at World’s Largest Biotechnology Conference

Aachen (Germany) / Chicago, IL (USA), April 19, 2013 – Grünenthal Group is pleased to announce their active participation in the 2013 BIO International Convention, the world’s largest event for the biotechnology industry. The family owned, research driven pharmaceutical company headquartered in Aachen, Germany, will be sharing with the Biotech community exciting developments in the NCE pipeline for pain and inflammation as well as the tamper-resistant formulation technology INTAC®.

More ...

16 Apr 2013

Grünenthal Position on FDA decision on abuse deterrent formulation of Oxycontin drugs

Aachen, 17th April 2013 – Grünenthal is pleased with the U.S. Food and Drug Administration’s (FDA) recent decisions regarding abuse deterrent formulations (ADF) and prescription opioids. In its response to a citizen petition by Purdue, generic equivalents to the reformulated abuse deterrent formulation of OxyContin will be required to have similar abuse deterrent properties and undergo specific testing requirements to demonstrate these properties.

More ...